Systematic Review on the Effectiveness and Outcomes of Nivolumab Treatment Schemes in Advanced and Metastatic Cervical Cancer

• Published in: Diseases Vol. 12; no. 4; p. 77
• Main Authors: Petre, Ion, Vernic, Corina, Petre, Izabella, Vlad, Cristian Sebastian, Sipos, Simona Ioana, Bordianu, Anca, Luciana, Marc, Dragomir, Radu Dumitru, Fizedean, Camelia Melania, Daliborca, Cristina Vlad
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-04-2024
• Subjects: Analysis; Cancer; Cancer therapies; Care and treatment; Cervical cancer; Cervix; Clinical outcomes; Clinical trials; Combination therapy; Disease control; Drug therapy; gynecology; Immune checkpoint inhibitors; Immune system; Ligands; Metastases; Metastasis; Oncology; Oncology, Experimental; Papillomavirus infections; Patient outcomes; Patients; PD-1 protein; PD-L1 protein; Quality of life; Response rates; Systematic review; Toxicity; Romania; gynecology; cervical cancer; oncology
• ISSN: 2079-9721; 2079-9721
• DOI: 10.3390/diseases12040077

Advanced and metastatic cervical cancer remains a formidable challenge in oncology, with immune checkpoint inhibitors such as the PD-1 inhibitor nivolumab emerging as a potential therapeutic option. This systematic review rigorously assesses the effectiveness and outcomes of various nivolumab treatment regimens within this patient cohort, drawing from clinical trials and real-world evidence up to December 2023. Following a comprehensive search across PubMed, Scopus, and Embase, four studies were deemed eligible, involving a collective total of 80 patients. One preliminary trial data were excluded from the final analysis, as well as four other proceedings and abstracts on the efficacy and safety of nivolumab on advanced cervical cancer. The patients' average age across these studies was 48 years, with an average of 38% having an Eastern Cooperative Oncology Group (ECOG) performance status of 1. Notably, 64% of all patients were positive for high-risk HPV, and 71% exhibited PD-L1 positivity, indicating a substantial target population for nivolumab. The analysis revealed a pooled objective response rate (ORR) of 48%, with a disease control rate (DCR) averaging 71%. Moreover, progression-free survival (PFS) at 6 months was observed at an average rate of 50%, reflecting the significant potential of nivolumab in managing advanced stages of the disease. The review highlights the influence of PD-L1 status on response rates and underscores the enhanced outcomes associated with combination therapy approaches. By delineating the variability in treatment efficacy and pinpointing key factors affecting therapeutic response and survival, this systematic review calls for further investigations to refine nivolumab's clinical application, aiming to improve patient outcomes in advanced and metastatic cervical cancer.